LEADER 05284nam 2201693z- 450 001 9910557385403321 005 20231214132850.0 035 $a(CKB)5400000000042045 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68583 035 $a(EXLCZ)995400000000042045 100 $a20202105d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAdvances in Multiple Sclerosis Research-Series I 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (334 p.) 311 $a3-03943-947-2 311 $a3-03943-948-0 330 $aDesigning immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular multiple sclerosis, for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special Issue focused on delivery methods to be used for vaccines, immunotherapeutic approaches, drug design, and anti-inflammatories and their outcomes in preclinical studies and clinical trials. 606 $aMedicine$2bicssc 610 $amultiple sclerosis 610 $ainflammation 610 $aoxidative 610 $abiomarker 610 $asample size 610 $aautoimmune encephalitis 610 $aplasma exchange 610 $aautoimmunity 610 $aimmunotherapeutics 610 $aclinical outcomes 610 $amajor depression 610 $abupropion 610 $aS-adenosylmethionine 610 $avitamin D3 610 $ayoga 610 $acraniopharyngioma 610 $afractionated stereotactic radiation treatments 610 $asphenoid sinusitis 610 $acranial nerve-VI palsy 610 $aautoimmune diseases 610 $aimmune thrombocytopenic purpura 610 $aalemtuzumab 610 $aantibodies against GluR3 peptide 610 $acognitive impairment 610 $adiagnosis 610 $aneuropsychological assessment 610 $ashort intracortical inhibition 610 $aintracortical facilitation 610 $afampridine 610 $awalking disability 610 $aTSPAN32 610 $atetraspanins 610 $acellular immunity 610 $amemory T cells 610 $atDCS 610 $aneuroimaging 610 $apositron emission tomography 610 $acerebral blood flow 610 $aprobiotics 610 $aStreptococcus thermophilus 610 $aST285 610 $aMBP83?99 peptide 610 $amannan 610 $aimmune modulation 610 $aagonist peptide 610 $agut microbiome 610 $agut?brain axis 610 $ametagenomics 610 $adisease-modifying treatments 610 $aMS 610 $avaccine 610 $aimmunomodulation 610 $acarriers 610 $aB cell receptor 610 $adelivery methods 610 $aimmunotherapy 610 $amonoclonal antibodies 610 $aT cell receptor 610 $atolerance 610 $adiagnostic markers 610 $aimmunoglobulins 610 $akappa 610 $afree light chains 610 $aantigen-specific immunotherapies 610 $atolerogenic vaccines 610 $atolerance induction 610 $acentral nervous system 610 $amyelin peptides 610 $amyelin basic protei 610 $aproteolipid protein 610 $amyelin oligodendrocyte glycoprotein 610 $ananotechnology 610 $adrug delivery nanosystems 610 $alipids 610 $apolymers 610 $avaccines 610 $ananoparticles 610 $aantigen-specific immunotherapy 610 $aexperimental autoimmune encephalomyelitis 610 $aneurodegeneration 610 $achloroquine 610 $aEAE 610 $adendritic cells 610 $amicroglia 610 $aastrocytes 610 $aoligodendrocytes 610 $aconformational analysis 610 $apeptides 610 $aaltered peptide ligands 610 $aNMR spectroscopy 610 $aNOE-constraints 610 $amolecular dynamic 610 $atrimolecular complex 610 $aMultiple Sclerosis 610 $aearly-onset 610 $aadult-onset 610 $aHuman Leucocyte Antigens 610 $aimmunogenetics 610 $aclinical phenotype 610 $aclinical outcome 610 $atherapeutics 610 $aantibody detection 610 $aELISA 610 $amultivalency 610 $aN-glucosylated peptide epitopes 610 $apeptide 610 $aconjugation 610 $aMOG35-55 610 $aGraphite/SiO2 electrode 610 $avoltammetry 610 $aHPLC 610 $aMS drugs 615 7$aMedicine 700 $aMatsoukas$b John$4edt$01309053 702 $aApostolopoulos$b Vasso$4edt 702 $aMatsoukas$b John$4oth 702 $aApostolopoulos$b Vasso$4oth 906 $aBOOK 912 $a9910557385403321 996 $aAdvances in Multiple Sclerosis Research-Series I$93029272 997 $aUNINA